Novavax Inc - NVAX STOCK NEWS

Novavax, Inc. (NASDAQ: NVAX) has partnered with FUJIFILM Diosynth Biotechnologies to manufacture bulk drug substance for its COVID-19 vaccine candidate, NVX-CoV2373. This collaboration is part of Novavax’s $1.6 billion funding from the U.S. government’s Operation Warp Speed, aimed at providing millions of vaccine doses by late 2020. Initial production has begun at FUJIFILM’s North Carolina facility, supporting a pivotal Phase 3 clinical trial expected to start in fall 2020. The vaccine is based on proprietary nanoparticle technology and aims to demonstrate safety and efficacy through extensive trials.

Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D. will present on the progress of NVX-CoV2373, its COVID-19 vaccine candidate, at the 2nd International Society for Vaccines Virtual Congress on July 21, 2020, at 9:55 a.m. ET. The NVX-CoV2373 vaccine is designed using recombinant nanoparticle technology and is funded by the U.S. Government with up to $1.6 billion through Operation Warp Speed. The Phase 1 clinical trial commenced in May 2020, with preliminary results expected in July 2020.

Novavax, Inc. (Nasdaq: NVAX) announced its selection for Operation Warp Speed, receiving a $1.6 billion award to advance its COVID-19 vaccine, NVX-CoV2373. This funding will support late-stage clinical trials, including a pivotal Phase 3 trial with up to 30,000 subjects, and large-scale manufacturing of 100 million doses. Preliminary safety results from a Phase 1/2 trial are expected by late July 2020, with additional support from CEPI amounting to $388 million. This partnership aims to expedite vaccine delivery amid the COVID-19 pandemic.

Novavax, Inc. (NASDAQ: NVAX) announced the appointment of Frank Czworka as Senior Vice President, Global Sales, and the promotion of Brian Webb to Senior Vice President, Manufacturing. Czworka, with over 20 years of experience, has previously held senior roles in biopharmaceutical sales and marketing. Webb has been instrumental in expanding manufacturing capabilities. The company aims to advance its COVID-19 vaccine candidate, NVX-CoV2373, and its quadrivalent influenza nanoparticle vaccine, NanoFlu, to the market, intending to positively impact global health.

Novavax (NASDAQ: NVAX) announced the appointment of Ben Machielse as Executive Vice President, CMC, on June 29, 2020. Machielse will oversee manufacturing and regulatory functions as the company advances its COVID-19 vaccine candidate, NVX-CoV2373. Other leadership promotions include John Trizzino as Chief Business Officer and CFO, John Herrmann III as Chief Legal Officer, and Jill Hoyt as Chief Human Resources Officer. Novavax is ramping up its manufacturing capacity for its vaccines, which include NVX-CoV2373 and NanoFlu, with clinical trial results expected soon.

Novavax, a biotechnology company focused on vaccines, will have its Chief Business Officer, John J. Trizzino, participate in the H.C. Wainwright Virtual Fireside Chat on June 25, 2020, at 10:00 a.m. ET. The discussion will center on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This candidate is part of Novavax's broader mission to develop innovative vaccines, including the NanoFlu™, which recently succeeded in a Phase 3 trial. More insights can be found on Novavax's website.

Novavax, Inc. (NASDAQ: NVAX) has appointed David Mott as an independent director of its Board, enhancing its leadership team with his extensive experience in biopharmaceuticals. Mott, who recently acquired nearly 65,000 shares of Novavax, brings over 30 years of management and investment expertise. His appointment comes as Novavax ramps up efforts in developing its COVID-19 vaccine (NVX-CoV2373) and prepares for regulatory submissions for NanoFlu™. Mott will also serve on the Compensation Committee, aiming to support the company's mission against serious infectious diseases.

Novavax (NASDAQ: NVAX) announced a private placement agreement to sell Series A Convertible preferred stock to RA Capital Management, converting into 4,388,852 shares of common stock at the June 12 closing price. The deal will provide Novavax with gross proceeds of approximately $200 million. This funding is expected to bolster Novavax's ongoing vaccine development efforts against COVID-19 and influenza. The preferred shares do not have voting rights and are not entitled to dividends. The transaction is part of Novavax's strategy to enhance its financial position and facilitate critical vaccine trials.

Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D., President of Research and Development, will participate in a panel discussion on COVID-19 vaccines at the 2020 BIO Digital conference on June 9 at 11:30 a.m. EDT. The panel will explore the complexities of vaccine development and the importance of collaboration in bringing vaccines to market. Additionally, Novavax is advancing its NVX-CoV2373 vaccine candidate for COVID-19 with Phase 1 results expected in July 2020, alongside positive Phase 3 results for its NanoFlu vaccine targeting influenza.